Follow
Promore Pharma AB
Nasdaq First North Sweden (Sweden)
Promore Pharma AB is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop pharmaceuticals for indications where very few efficacious prescription pharmaceuticals are available addressing high unmet medical needs. Promore Pharma's two projects are in late stage clinical development phase and have a very strong safety profile since they are based on innate substances that are administered locally. The project, PXL01, that will be used for preventi Promore Pharma AB is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop pharmaceuticals for indications where very few efficacious prescription pharmaceuticals are available addressing high unmet medical needs. Promore Pharma's two projects are in late stage clinical development phase and have a very strong safety profile since they are based on innate substances that are administered locally. The project, PXL01, that will be used for prevention of post-surgical adhesions and scars, is being prepared for clinical phase III-studies in patients undergoing tendon repair surgery in the hand. LL -37 is being evaluated in a clinical phase IIb study in patients with venous leg ulcers (VLU).

Read more

Sector:
HEALTH CARE
Sector:
TECHNOLOGY
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Show archived
Type
Ticker
ISIN
Market
SHARE
PROMO
SE0009947740
Nasdaq First North Sweden
Sweden (SE)
Details of share in Promore Pharma AB with ticker PROMO
Status
Active
Order book id
Amount of instruments
36 428 362
Par value
0.0400
Market cap
Currency
SEK
Segment
First North
First trading date
03 Jul 2017
Terms
Type
Price
Pre-money valuation
Time
Files
IPO
23.30 SEK
395M SEK
08 Jun - 22 Jun 2017
IPO in Promore Pharma AB
Market
Nasdaq First North Sweden
Subscription period
08 Jun - 22 Jun 2017
Subscription price
23.30 SEK
Price per share
23.30 SEK
Target to raise
106 000 000 SEK
Types
Share issue
Pre-money valuation
395 000 000 SEK
Subscription block size
1
Minimum subscription
250
Record date
Offer status
Closed
Listing status
Listed
First trading date
03 Jul 2017
Issue terms
Open to the public.
Comments for offer & related information
Promore Pharma will be listed on First North on July 3, 2017.
The company issues 4 549 358 units. Each unit consists of one (1) share and two (2) warrants of the TO1 series. Holders of warrants are entitled to subscribe for three (3) warrants to one (1) share at a subscription price corresponding to 70 percent of a volume weighted average of the trading price of the Company's shares during the period 21 - 31 January 2019. However, the subscription price may not less than SEK 23.30 per share or exceed SEK 46.60 per share. Subscriptions can be made during the period 4 - 22 February 2019.
Promore Pharma has received written subscription commitments from the Company's principal owner Midroc New Technology AB, Rosetta Capital IV Sarl and PharmaResearch Products Ltd, as well as written guarantee commitments totaling approximately 72% of the issue proceeds.
In the event the issue becomes fully subscribed and all pending subscription options are exercised, the Company will receive an additional SEK 81.6 million at the lowest subscription price (after transaction costs).
Type
Price
Pre-money valuation
Time
Files
Exercise
23.30-46.60 SEK
21 Jan - 31 Jan 2019
Option exercise terms for PROMO TO1
Former ticker
PROMO TO 1
Market
Nasdaq First North Sweden
Exercise period(s)
21 Jan - 31 Jan 2019
Exercise price range
23.30-46.60 SEK
Exercise final price
Status
Closed
Issue terms
Three (3) equity rights give the right to subscribe for one (1) new share in the Company. Strike price shall be 70% of the volume weighted average price per share during the period January 21 – January 31, 2019. However, strike price shall be a minimum of 23.30 SEK per share and a maximum of 46.60 SEK per share
Type
Price
Pre-money valuation
Time
Files
New issue
3.71 SEK
75M SEK
13 Nov - 28 Nov 2019
Share issue in Promore Pharma AB
Market
Nasdaq First North Sweden
Subscription period
13 Nov - 28 Nov 2019
Subscription price
3.71 SEK
Price per share
3.71 SEK
Target to raise
75 000 000 SEK
Types
Share issue
Pre-money valuation
75 000 000 SEK
Subscription block size
Minimum subscription
Record date
06 Oct 2019
Offer status
Closed
Listing status
Listed
Issue terms
Rights issue. Preference right 1:1. For each (1) share held per record day (06.10.2019), one (1) subscription right is obtained. One (1) subscription right entitles the holder to subscribe for one (1) new share.
Comments for offer & related information
The company issues 20 235 090 shares.
Midroc New Technology AB, which holds approximately 33.7 percent of the Company's outstanding shares, and PharmaResearch Products Ltd, which holds approximately 23.6 percent of the Company's outstanding shares, have undertaken to subscribe for approximately SEK 25 million, corresponding to its pro rata share , and SEK 10 million respectively in the Rights Issue. In total, these subscription commitments amount to approximately SEK 35 million, corresponding to 47.0 percent of the Rights Issue.
In addition, Promore Pharma has received issue guarantees from external investors of up to approximately SEK 25 million, corresponding to up to 33.0 percent of the Rights Issue. In total, the Rights Issue is thus guaranteed up to an amount of approximately SEK 60 million, corresponding to approximately 80 percent of the issue amount.
Type
Ticker
ISIN
Market
SHARE
PROMO
SE0009947740
Nasdaq First North Sweden
Sweden (SE)
Details of share in Promore Pharma AB with ticker PROMO
Status
Active
Order book id
Amount of instruments
36 428 362
Par value
0.0400
Market cap
Currency
SEK
Segment
First North
First trading date
03 Jul 2017
Terms
Type
Price
Pre-money valuation
Time
Files
IPO
23.30 SEK
395M SEK
08 Jun - 22 Jun 2017
IPO in Promore Pharma AB
Market
Nasdaq First North Sweden
Subscription period
08 Jun - 22 Jun 2017
Subscription price
23.30 SEK
Price per share
23.30 SEK
Target to raise
106 000 000 SEK
Types
Share issue
Pre-money valuation
395 000 000 SEK
Subscription block size
1
Minimum subscription
250
Record date
Offer status
Closed
Listing status
Listed
First trading date
03 Jul 2017
Issue terms
Open to the public.
Comments for offer & related information
Promore Pharma will be listed on First North on July 3, 2017.
The company issues 4 549 358 units. Each unit consists of one (1) share and two (2) warrants of the TO1 series. Holders of warrants are entitled to subscribe for three (3) warrants to one (1) share at a subscription price corresponding to 70 percent of a volume weighted average of the trading price of the Company's shares during the period 21 - 31 January 2019. However, the subscription price may not less than SEK 23.30 per share or exceed SEK 46.60 per share. Subscriptions can be made during the period 4 - 22 February 2019.
Promore Pharma has received written subscription commitments from the Company's principal owner Midroc New Technology AB, Rosetta Capital IV Sarl and PharmaResearch Products Ltd, as well as written guarantee commitments totaling approximately 72% of the issue proceeds.
In the event the issue becomes fully subscribed and all pending subscription options are exercised, the Company will receive an additional SEK 81.6 million at the lowest subscription price (after transaction costs).
Type
Price
Pre-money valuation
Time
Files
New issue
3.71 SEK
75M SEK
13 Nov - 28 Nov 2019
Share issue in Promore Pharma AB
Market
Nasdaq First North Sweden
Subscription period
13 Nov - 28 Nov 2019
Subscription price
3.71 SEK
Price per share
3.71 SEK
Target to raise
75 000 000 SEK
Types
Share issue
Pre-money valuation
75 000 000 SEK
Subscription block size
Minimum subscription
Record date
06 Oct 2019
Offer status
Closed
Listing status
Listed
Issue terms
Rights issue. Preference right 1:1. For each (1) share held per record day (06.10.2019), one (1) subscription right is obtained. One (1) subscription right entitles the holder to subscribe for one (1) new share.
Comments for offer & related information
The company issues 20 235 090 shares.
Midroc New Technology AB, which holds approximately 33.7 percent of the Company's outstanding shares, and PharmaResearch Products Ltd, which holds approximately 23.6 percent of the Company's outstanding shares, have undertaken to subscribe for approximately SEK 25 million, corresponding to its pro rata share , and SEK 10 million respectively in the Rights Issue. In total, these subscription commitments amount to approximately SEK 35 million, corresponding to 47.0 percent of the Rights Issue.
In addition, Promore Pharma has received issue guarantees from external investors of up to approximately SEK 25 million, corresponding to up to 33.0 percent of the Rights Issue. In total, the Rights Issue is thus guaranteed up to an amount of approximately SEK 60 million, corresponding to approximately 80 percent of the issue amount.
Type
Ticker
ISIN
Market
OPTION
PROMO TO1
SE0009997158
Nasdaq First North Sweden
Sweden (SE)
Details of option in Promore Pharma AB with ticker PROMO TO1
Status
Archived
Order book id
140252
Amount of instruments
6 523 560
Market cap
Currency
SEK
Segment
First North
First trading date
Terms
Three (3) equity rights give the right to subscribe for one (1) new share in the Company. Strike price shall be 70% of the volume weighted average price per share during the period January 21 – January 31, 2019. However, strike price shall be a minimum of 23.30 SEK per share and a maximum of 46.60 SEK per share
Type
Price
Pre-money valuation
Time
Files
Exercise
23.30-46.60 SEK
21 Jan - 31 Jan 2019
Option exercise terms for PROMO TO1
Former ticker
PROMO TO 1
Market
Nasdaq First North Sweden
Exercise period(s)
21 Jan - 31 Jan 2019
Exercise price range
23.30-46.60 SEK
Exercise final price
Status
Closed
Issue terms
Three (3) equity rights give the right to subscribe for one (1) new share in the Company. Strike price shall be 70% of the volume weighted average price per share during the period January 21 – January 31, 2019. However, strike price shall be a minimum of 23.30 SEK per share and a maximum of 46.60 SEK per share
People
Number of Employees
1 people
Jonas Göran Ekblom
CEO
Göran Pettersson
Chairman of the board
Göran Pettersson
Board member
Marianne Dicander Alexandersson
Board member
Torsten Goesch
Board member
Satyendra Kumar
Board member
Göran Linder
Board member
Company Details
Sector
HEALTH CARE, TECHNOLOGY

Address
Fogdevreten 2
Zip code
171 65
City/district
Solna
Country
Sweden (SE)
Registration number
556639-6809
LEI code
549300FJYXYRTU6R3M15
First trade date
03 Jul 2017
Registration date
29 Jan 2003
Short name
Promore Pharma

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date